longevity science
Unmask Longevity Science - Telomerase Activators vs Senolytics ROI
Telomerase activators and senolytics each offer distinct ROI profiles, with telomerase promising higher long-term revenue streams - projected ARR of $350 million within seven years - while senolytics deliver quicker market entry and steadier returns. Investors hear the hype about "the ultimate anti-aging drug," yet the data show